GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion Stock Buyback, Raises Long-Term Annual Sales Forecast To Over $50 Billion
Benzinga · 411 days
High Materiality8/10
AI Summary
GSK reported Q4 sales of $10.40 billion, beating analyst expectations. Vaccine sales fell 14%, with Arexvy significantly impacted by low demand. Specialty Medicines grew 14%, primarily driven by HIV and asthma drug sales. GSK plans £2 billion share buyback over 18 months, boosting EPS outlook. Long-term sales outlook raised to over £40 billion by 2031.
Sentiment Rationale
GSK's better-than-expected sales and share buyback illustrate solid financial health, similar to past recovery trends.
Trading Thesis
The guidance for growth and significant share buybacks may take time to stabilize stock prices.
Market-Moving
- GSK reported Q4 sales of $10.40 billion, beating analyst expectations.
- Vaccine sales fell 14%, with Arexvy significantly impacted by low demand.
- Specialty Medicines grew 14%, primarily driven by HIV and asthma drug sales.
Key Facts
- GSK reported Q4 sales of $10.40 billion, beating analyst expectations.
- Vaccine sales fell 14%, with Arexvy significantly impacted by low demand.
- Specialty Medicines grew 14%, primarily driven by HIV and asthma drug sales.
- GSK plans £2 billion share buyback over 18 months, boosting EPS outlook.
- Long-term sales outlook raised to over £40 billion by 2031.
Companies Mentioned
- GSK (GSK)
Earnings
The financial results and future growth potential could lead to increased investor confidence in GSK.